

**PRODUCT: LEVETIRACETAM**

ITEMS	SPECIFICATIONS
<b>DESCRIPTION</b>	White or almost white powder
<b>IDENTIFICATION</b> a) By IR  b) By Chiral HPLC (Enantiomeric purity)	Should conform to standard  The retention time of the major peak should correspond to the retention time of S (-) Levetiracetam peak obtained in the chromatogram of system suitability solution
<b>SOLUBILITY</b>	Very soluble in water, soluble in acetonitrile and practically insoluble in hexane
<b>WATER CONTENT BY KF (Use 500 mg sample in methanol as medium)</b>	NMT 0.50% w/w
<b>HEAVY METALS</b> (Use 2.0g sample in 20 ml of water; 10 ml of 1 ppm lead standard solution; EP method –A)	Less than 10 ppm
<b>SULPHATED ASH (Use 1.0g of sample)</b>	NMT 0.10% w/w
<b>APPEARANCE OF SOLUTION</b> (Dissolve 2.0 g of sample in 10 ml of water)	The solution should be clear and not more intensely coloured than reference solution BY <sub>6</sub>
<b>RESIDUAL SOLVENTS</b> a) Dichloromethane b) Ethyl acetate (By headspace GC)	NMT 600 ppm NMT 5000 ppm

<b>ENANTIOMERIC PURITY</b> <b>Pharmaeuropa impurity D</b> <b>[(+)-Levetiracetam]</b> <b>(By HPLC, percentage area normalization)</b>	NMT 0.80
<b>RELATED SUBSTANCES -Test 1 (By HPLC)</b> ➤ <b>2-Aminobutyric acid</b> ➤ <b>USP Levetiracetam related compound B</b>	NMT 0.05% w/w NMT 0.10% w/w
<b>RELATED SUBSTANCES-Test 2 (By HPLC)</b> ➤ <b>Pharmaeuropa impurity A</b> ➤ <b>USP Levetiracetam related compound A</b> ➤ <b>Pharmaeuropa impurity C</b> ➤ <b>Highest unknown impurity</b> ➤ <b>Total unknown impurities</b> ➤ <b>Total impurities (Sum of related substance Test 1 and Test 2 excluding Pharmaeuropa impurity C)</b>	NMT 0.30% w/w NMT 0.05% w/w NMT 0.025% w/w NMT 0.05% w/w NMT 0.10% w/w NMT 0.40% w/w
<b>ASSAY BY HPLC</b> <b>(C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>, on anhydrous basis)</b>	98.0% w/w ~ 102.0% w/w